Embecta (Nasdaq:EMBC) today revealed its phased plan to create value and shift priorities toward broader medical applications ...

Despite winning an FDA green light nearly three months ago for its first wearable insulin delivery system, Embecta is now discontinuing its patch pump program as part of a broader restructuring ...

As a result of the restructuring, Embecta expects pretax savings between $7 million and $8 million during the second half of ...

Embecta now expects revenues between $1.073 billion and $1.09 billion. This would mark a sales dip of between 4.4% and 2.9% year-over-year. It’s also a decrease from previous projections for between ...

CEO of Embecta (EMBC) said, “As our stand-up work nears completion and following an in-depth review of our portfolio and strategy, we have decided to discontinue our insulin patch pump program ...

Embecta stock may seem undervalued at first glance, but heavy debt, declining pen needle revenues, and competition signal ...

Embecta has secured an FDA clearance for its first wearable insulin delivery system, with a patch pump designed for people with either Type 1 or Type 2 diabetes. The fully disposable device ...

For such people, the on-market patch pumps may not hold enough insulin to meet their needs for three days.2 For example, a recent embecta-sponsored study3 showed that a 300-unit insulin reservoir ...

embecta continues to advance its patch pump development program, with plans for a closed-loop version including an insulin-dosing algorithm in a future FDA submission.

Embecta (NASDAQ:EMBC) said it has submitted a 510(k) premarket application to the FDA for approval of its insulin patch pump for the treatment of type 2 diabetes. The company added that it plans ...

PARSIPPANY, N.J., April 28, 2025 (GLOBE NEWSWIRE) -- Embecta Corp. ("embecta") (Nasdaq: EMBC), a global diabetes care company with a 100-year legacy in insulin delivery, will hold an Analyst and ...

there is a critical unmet need among the T2D population for pumps with a larger insulin reservoir,” said Henry Anhalt, D.O., Chief Medical Officer, embecta. “As our mission is to make life ...